The standard treatment for patients with newly diagnosed multiple myeloma (NDMM) is a combination of melphalan, prednisone, and thalidomide (MPT). The phase IIITMM-020/IFM 07 01 trial compared the efficacy and safety of combining lenalidomide and low-dose dexamethasone (Rd) with MPT. The study included 1,623 patients ineligible for stem-cell transplantation, due to age or other factors, who were randomly assigned to three treatment groups: continuous Rd until disease progression, Rd for 72 weeks, or MPT for 72 weeks. Patients treated with continuous Rd were less likely (28%) to experience disease progression or death than those patients treated with MPT. The safety profiles of the two treatment regimens were similar, although patients treated with Rd showed fewer secondary haematological malignancies than those treated with MPT.
References
Facon, T. et al. Initial phase III results of the first (frontline investigation of lenalidomide + dexamethasone versus standard thalidomide) trial (MM-020/IFM 07 01) in newly diagnosed multiple myeloma patients ineligible for stem cell transplantation [abstract]. Blood 122, a2 (2013)
Rights and permissions
About this article
Cite this article
Options for patients ineligible for stem-cell transplantation. Nat Rev Clin Oncol 11, 67 (2014). https://doi.org/10.1038/nrclinonc.2013.240
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.240